Intellia Thera CS (NTLA) Stock Price, Quote & News

Company Profile

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-20...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 285 6200

Website: www.intelliatx.com

Address:

40 Erie Street, Suite 130, Cambridge, United States

Michaelthoaicaonguyen Jun. 25 at 1:27 AM

$NTLA $ABAT $SLNH More than 3/4 of the market is down red. Crypto same thing. IMO the market is reacting to the PCE inflation report tomorrow. Market adjustments is part of the game. So for all you traders/penny scrapers be patience, but I don’t trade so I can careless For the long bulls if you did your DD and I did mine, we either add more or just chill. That is it. Nothing more to say.

0 · Reply

Michaelthoaicaonguyen Jun. 25 at 1:16 AM

$IXHL $NTLA $ABAT $SLNH Tomorrow Thursday 6/25/2026 @ 8:30 am ET Fed will report PCE. If I’m not mistaken the market would be focusing on the core PCE of MoM & YoY. Keep your fingers cross🤞

0 · Reply

the_end Jun. 24 at 7:50 PM

$NTLA micron earnings may cause a shock in the markets maybe ... we should be fine hopefully ...

1 · Reply

GoodTidings Jun. 24 at 6:27 PM

$NTLA The pool of retail flippers that shorts where hoping on to cut their losses gets smaller by the day... You know how this will end... 😎😎😎

0 · Reply

BioB123 Jun. 24 at 5:50 PM

$NTLA

0 · Reply

MoonkidSamwise Jun. 24 at 4:43 PM

$NTLA I have 900 shares, up for 15%. That is my commitment on NTLA. CRISPR tec has potential. If this is successful, it is really successful. GL all!

0 · Reply

the_end Jun. 24 at 4:35 PM

$NTLA this has happened two times now. the entire gene therapy stocks got a run. earlier was a pump and dump. this one after HHS statement this week ? or successful trials or FDA approval ? wait and watch ... enjoy while it lasts

0 · Reply

accretivewealth Jun. 24 at 4:27 PM

$NTLA think it only grinds for a while longer after the recent rise on the HAE Phase 3 news, testing the most recent high. Then, perhaps you get a second pop higher as shorts may have to capitulate at some point. Always have to remind myself I am buying not just a stock price, but business value. The implications of the Phase 3 results far extend HAE.

0 · Reply

cyberchief Jun. 24 at 4:24 PM

$NTLA today 16,30

0 · Reply

Shirzo Jun. 24 at 4:24 PM

$NTLA

0 · Reply

Intellia Therapeutics rises 12.9%

2026-06-17T14:07:55.000Z - 7 days ago

Intellia Therapeutics rises 10.7%

2026-06-14T20:35:58.000Z - 10 days ago

Intellia Therapeutics presents additional results from Phase 3 HAELO trial

Jun 13, 2026, 7:30 AM EDT - 11 days ago

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Jun 9, 2026, 9:00 AM EDT - 15 days ago

Intellia Therapeutics Transcript: AGM 2026

Jun 5, 2026, 4:05 PM EDT - 19 days ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 3, 2026, 4:55 PM EDT - 21 days ago

Intellia Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 1, 2026, 7:30 AM EDT - 23 days ago

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

May 20, 2026, 2:35 PM EDT - 5 weeks ago

Intellia Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

2026-05-13T10:34:18.000Z - 6 weeks ago

Intellia Therapeutics price target raised to $17 from $13 at Bernstein

2026-05-13T10:28:35.000Z - 6 weeks ago

Intellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright

May 12, 2026, 6:40 PM EDT - 6 weeks ago

Intellia Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T16:07:18.000Z - 6 weeks ago

Intellia Therapeutics price target lowered to $19 from $20 at BofA

2026-05-12T11:12:55.000Z - 6 weeks ago

Intellia Therapeutics price target lowered to $49 from $58 at Canaccord

2026-05-11T17:26:11.000Z - 6 weeks ago

Intellia Therapeutics reports Q1 EPS (81c), consensus (90c)

May 11, 2026, 7:30 AM EDT - 6 weeks ago

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

May 11, 2026, 7:30 AM EDT - 6 weeks ago

Intellia Therapeutics Earnings release: Q1 2026

May 11, 2026, 7:30 AM EDT - 6 weeks ago

Intellia Therapeutics Quarterly report: Q1 2026

May 5, 2026, 7:30 AM EDT - 7 weeks ago

Intellia Therapeutics to Participate in Upcoming Investor Conferences

2026-05-02T00:11:02.000Z - 7 weeks ago

Cathie Wood’s ARK Investment buys 141K shares of Intellia Therapeutics today

Apr 30, 2026, 8:00 AM EDT - 7 weeks ago

Intellia Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 7 weeks ago

Intellia Therapeutics Proxy statement: Proxy filing

2026-04-30T03:26:02.000Z - 2 months ago

Cathie Wood’s ARK Investment buys 2.4M shares of Intellia Therapeutics today

2026-04-29T15:02:56.000Z - 2 months ago

Intellia Therapeutics 16.7M share Secondary priced at $10.75

Apr 29, 2026, 7:00 AM EDT - 2 months ago

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

2026-04-29T00:13:03.000Z - 2 months ago

Cathie Wood’s ARK Investment buys 596K shares of Intellia Therapeutics today

2026-04-28T13:00:00.000Z - 2 months ago

Cathie Wood Offloads Rocket Lab Stock (RKLB) Despite 3% Jump, Buys the Dip in Intellia (NTLA)

ARKG ARKK ARKQ RKLB

2026-04-28T11:21:47.000Z - 2 months ago

Intellia Therapeutics price target raised to $13 from $7 at Baird

2026-04-28T11:12:55.000Z - 2 months ago

Intellia Therapeutics price target raised to $58 from $48 at Canaccord

2026-04-28T10:29:23.000Z - 2 months ago

Intellia Therapeutics price target raised to $9 from $8 at Goldman Sachs

Apr 27, 2026, 4:01 PM EDT - 2 months ago

Intellia Announces Proposed Public Offering of Common Stock

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Intellia Therapeutics Transcript: Study result

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Intellia Therapeutics Press release: Study result

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Intellia Therapeutics Slides: Study result

Apr 27, 2026, 7:06 AM EDT - 2 months ago

Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial

Apr 27, 2026, 7:01 AM EDT - 2 months ago

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial

Apr 27, 2026, 7:00 AM EDT - 2 months ago

Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema

Apr 27, 2026, 7:00 AM EDT - 2 months ago

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Apr 24, 2026, 4:05 PM EDT - 2 months ago

Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

Mar 9, 2026, 8:40 AM EDT - 3 months ago

Intellia Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 1:10 PM EST - 4 months ago

Intellia Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 7:30 AM EST - 4 months ago

Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026

Mar 2, 2026, 7:40 AM EST - 4 months ago

US FDA lifts clinical hold on Intellia's heart disease gene therapy trial

Mar 2, 2026, 7:30 AM EST - 4 months ago

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

Feb 26, 2026, 8:00 AM EST - 4 months ago

Intellia Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:00 AM EST - 4 months ago

Intellia Therapeutics Annual report: Q4 2025

Feb 26, 2026, 8:00 AM EST - 4 months ago

Intellia Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 7:30 AM EST - 4 months ago

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Feb 19, 2026, 7:30 AM EST - 4 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Jan 27, 2026, 8:13 AM EST - 5 months ago

US FDA lifts clinical hold on Intellia's nerve disease trail

Jan 14, 2026, 12:00 PM EST - 5 months ago

Intellia Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 7:00 AM EST - 5 months ago

Intellia Therapeutics Slides: Corporate presentation

Jan 7, 2026, 7:30 AM EST - 6 months ago

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 10, 2025, 3:17 PM EST - 8 months ago

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Nov 8, 2025, 5:13 PM EST - 8 months ago

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Nov 6, 2025, 9:30 AM EST - 8 months ago

Intellia Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 9:30 AM EST - 8 months ago

Intellia Therapeutics Earnings release: Q3 2025

Oct 29, 2025, 5:11 PM EDT - 8 months ago

US FDA places clinical hold on Intellia's two gene-editing treatment trials

Oct 27, 2025, 8:30 AM EDT - 8 months ago

Intellia Therapeutics Transcript: Study Update

Oct 27, 2025, 8:30 AM EDT - 8 months ago

Intellia Therapeutics Press release: Study Update

Oct 27, 2025, 7:38 AM EDT - 8 months ago

Intellia pauses late-stage trials of gene-editing treatment after serious liver event

Oct 27, 2025, 7:30 AM EDT - 8 months ago

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Sep 30, 2025, 7:00 AM EDT - 9 months ago

Intellia Therapeutics Slides: Company Presentation

Sep 25, 2025, 9:52 AM EDT - 9 months ago

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Sep 18, 2025, 7:30 AM EDT - 9 months ago

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Sep 1, 2025, 8:43 AM EDT - 10 months ago

Why big players are pouring millions in THIS biotech stock

Aug 7, 2025, 8:00 AM EDT - 11 months ago

Intellia Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 11 months ago

Intellia Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 11 months ago

Intellia Therapeutics Earnings release: Q2 2025

Aug 1, 2025, 7:30 AM EDT - 11 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jul 31, 2025, 7:30 AM EDT - 11 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

Jun 15, 2025, 10:45 AM EDT - 1 year ago

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Jun 11, 2025, 9:00 AM EDT - 1 year ago

Intellia Therapeutics Transcript: AGM 2025

May 18, 2025, 7:25 AM EDT - 1 year ago

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

May 13, 2025, 7:20 PM EDT - 1 year ago

Intellia Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 8, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Earnings release: Q1 2025

May 7, 2025, 7:00 AM EDT - 1 year ago

Intellia Therapeutics Slides: Corporate Presentation

May 1, 2025, 7:30 AM EDT - 1 year ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 9:50 AM EDT - 1 year ago

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Apr 14, 2025, 10:58 AM EDT - 1 year ago

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

Michaelthoaicaonguyen Jun. 25 at 1:27 AM

0 · Reply

Michaelthoaicaonguyen Jun. 25 at 1:16 AM

$IXHL $NTLA $ABAT $SLNH Tomorrow Thursday 6/25/2026 @ 8:30 am ET Fed will report PCE. If I’m not mistaken the market would be focusing on the core PCE of MoM & YoY. Keep your fingers cross🤞

0 · Reply

the_end Jun. 24 at 7:50 PM

$NTLA micron earnings may cause a shock in the markets maybe ... we should be fine hopefully ...

1 · Reply

GoodTidings Jun. 24 at 6:27 PM

$NTLA The pool of retail flippers that shorts where hoping on to cut their losses gets smaller by the day... You know how this will end... 😎😎😎

0 · Reply

BioB123 Jun. 24 at 5:50 PM

$NTLA

0 · Reply

MoonkidSamwise Jun. 24 at 4:43 PM

$NTLA I have 900 shares, up for 15%. That is my commitment on NTLA. CRISPR tec has potential. If this is successful, it is really successful. GL all!

0 · Reply

the_end Jun. 24 at 4:35 PM

0 · Reply

accretivewealth Jun. 24 at 4:27 PM

0 · Reply

cyberchief Jun. 24 at 4:24 PM

$NTLA today 16,30

0 · Reply

Shirzo Jun. 24 at 4:24 PM

$NTLA

0 · Reply

GoodTidings Jun. 24 at 4:08 PM

$NTLA I think from a growth perspective it's like AMD... I stepped in $AMD when it was $12 and exit at $38... though I made a lot of money... Same story lots of shorts negative narratives and you name it... Same deceased short narrative and look at $AMD now... That's how I regard Intellia... Same potential... 😎😎😎

1 · Reply

GoodTidings Jun. 24 at 3:47 PM

$NTLA We are in the process of breaking out of this 6 months trading range... Everyone is getting used that we are soon going to reach to higher levels... 😎😎😎

1 · Reply

GoodTidings Jun. 24 at 3:44 PM

$NTLA Sector rotation from the hyped AI with over the top valuation to the undervalued gene editing cures that will start soon making billions... The best timing to enter before the crowd follows suite... 😎😎😎

0 · Reply

BillyBlanks77 Jun. 24 at 3:30 PM

$NTLA it will be glorious when we break $16 with nothing but blue skies ahead. The good news is we are holding at high 15’s on lite volume all week. Typically lite volume days the shorts would feast. Tells me they are no longer in control and it’s only a matter of time…

0 · Reply